IP Library Granted Patent US 12,098,422
Granted Patent B2
US 12,098,422 · App. 18/538,986 · Granted Sep 24, 2024

Methods and systems for detecting genetic variants

Inventors: AmirAli Talasaz (Atherton, CA); Helmy Eltoukhy (Atherton, CA); Stefanie Ann Ward Mortimer (Morgan Hill, CA)
Assignee: Guardant Health, Inc.
C12Q1/6869C12Q1/6886C12Q2535/122C12Q2600/158G16B15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,422
App. No.
18/538,986
Granted
Sep 24, 2024
Kind
B2
Abstract

Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.

Claims (28)

1. A method, comprising:

(a) providing a population of deoxyribonucleic acid (DNA) molecules having first and second complementary strands;

(b) tagging a plurality of the DNA molecules in the population with duplex tags comprising molecular barcodes to produce tagged parent polynucleotides, wherein the duplex tags are attached to both ends of a molecule of the plurality of the DNA molecules, wherein the molecular barcodes are attached to the plurality of the DNA molecules using more than a 20× excess of duplex tags as compared to the population of DNA molecules, wherein at least 20% of the DNA molecules from the population are tagged with the duplex tags;

(c) amplifying a plurality of the tagged parent polynucleotides to produce amplified progeny polynucleotides;

(d) sequencing at least a subset of the amplified progeny polynucleotides to produce a set of sequence reads; and

(e) reducing or tracking redundancy of a plurality of sequence reads from the set of sequence reads using at least sequencing information from the molecular barcodes of the duplex tags to determine distinct DNA molecules from among the tagged parent polynucleotides, wherein the distinct DNA molecules are determined based on (i) paired reads corresponding to sequence reads generated from a first tagged strand and a second tagged complementary strand derived from DNA molecules from among the tagged parent polynucleotides, or (ii) unpaired reads corresponding to sequence reads generated from a first tagged strand having no second tagged complementary strand derived from DNA molecules from among the tagged parent polynucleotides, wherein reducing or tracking the redundancy of the plurality of sequence reads comprises mapping at least a subset of the plurality of sequence reads to a reference sequence.

2. The method of claim 1 , wherein the population of DNA molecules is obtained or derived from a subject having cancer.

3. The method of claim 1 , wherein the population of DNA molecules comprises 1 nanogram (ng) to 100 ng of DNA molecules.

4. The method of claim 1 , wherein the molecular barcodes are ligated to the plurality of the DNA molecules using more than a 50× excess of duplex tags as compared to the population of DNA molecules.

5. The method of claim 4 , wherein the molecular barcodes are ligated to the plurality of the DNA molecules using more than an 80× excess of duplex tags as compared to the population of DNA molecules.

6. The method of claim 5 , wherein at least 40% of the DNA molecules from the population are tagged with the duplex tags.

7. The method of claim 1 , wherein the plurality of the DNA molecules is tagged with n different combinations of molecular barcodes, wherein n is at least 2 and no more than 100,000*z, wherein z is a mean of an expected number of duplicate molecules in the population of DNA molecules that map to identical start and stop positions on a reference sequence.

8. The method of claim 7 , wherein the plurality of the DNA molecules is tagged with n different combinations of molecular barcodes, wherein n is at least 2 and no more than 10,000*z, wherein z is a mean of an expected number of duplicate molecules in the population of DNA molecules that map to identical start and stop positions on a reference sequence.

9. The method of claim 8 , wherein the plurality of the DNA molecules is tagged with n different combinations of molecular barcodes, wherein n is at least 2 and no more than 1,000*z, wherein z is a mean of an expected number of duplicate molecules in the population of DNA molecules that map to identical start and stop positions on a reference sequence.

10. The method of claim 9 , wherein the plurality of the DNA molecules is tagged with n different combinations of molecular barcodes, wherein n is at least 2 and no more than 100*z, wherein z is a mean of an expected number of duplicate molecules in the population of DNA molecules that map to identical start and stop positions on a reference sequence.

11. The method of claim 7 , wherein z is between 2 and 8.

12. The method of claim 8 , wherein z is between 2 and 8.

13. The method of claim 12 , wherein:

(i) the subject has cancer,

(ii) wherein the plurality of the DNA molecules that are tagged in (b) are cell-free DNA (cfDNA) molecules, and

(iii) wherein the cfDNA molecules comprises 1 nanogram (ng) to 100 ng of cfDNA molecules.

14. The method of claim 1 , wherein the molecular barcodes have a length of 5 to 20 base pairs.

15. The method of claim 1 , further comprising, prior to the sequencing, enriching at least a subset of the amplified progeny polynucleotides for target regions of interest to produce enriched progeny polynucleotides.

16. The method of claim 15 , further comprising, prior to the sequencing, amplifying a plurality of the enriched progeny polynucleotides.

17. The method of claim 1 , wherein reducing or tracking the redundancy of the plurality of sequence reads comprises grouping the paired reads or the unpaired reads into families based at least in part on (i) the molecular barcodes associated with the paired reads or the unpaired reads, or (ii) a combination of sequence information from the molecular barcodes associated with the paired reads or the unpaired reads, and a start base position of a given sequence read at which the given sequence read is determined to start mapping to the reference sequence and a stop base position of the given sequence read at which the given sequence read is determined to stop mapping to the reference sequence.

18. The method of claim 1 , further comprising determining quantitative measures of (i) paired reads or (ii) unpaired reads that map to a genomic locus of the reference sequence.

19. The method of claim 18 , further comprising determining a quantitative measure of unseen sequence reads for which neither strand of the DNA molecule is detected from among the tagged parent polynucleotides, wherein the quantitative measure of unseen sequence reads is calculated based on the quantitative measure of the paired reads and the quantitative measure of the unpaired reads.

20. The method of claim 19 , further comprising determining with a programmed computer processor a total number of tagged parent polynucleotides that map to a locus of a reference sequence based on the quantitative measures of paired reads, unpaired reads, and unseen sequence reads.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2024
From: ELTOUKHY, HELMY; TALASAZ, AMIRALI; MORTIMER, STEFANIE ANN WARD
To: GUARDANT HEALTH, INC.
Reel/Frame 066450/0504 →
Continuity (14)
Continuation 18535485 · Dec 11, 2023
Continuation 18491071 · Oct 20, 2023
Continuation 18317550 · May 15, 2023
Continuation 17512587 · Oct 27, 2021
Continuation 17410903 · Aug 24, 2021
Continuation 17167974 · Feb 4, 2021
Continuation 16945124 · Jul 31, 2020
Continuation 16601168 · Oct 14, 2019
Continuation 15892178 · Feb 8, 2018
Continuation 14861989 · Sep 22, 2015
Continuation PCTUS2014072383 · Dec 24, 2014
Provisional Application 61948509 · Mar 5, 2014
Provisional Application 61921456 · Dec 28, 2013
Related Publication 20240240247A1 · Jul 18, 2024